This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Buy, Hold or Sell RTX Stock Post Q1 Earnings Release?
by Aparajita Dutta
Investors interested in RTX stock should avoid adding it to their portfolio, considering its premium valuation and downward revision in earnings estimates.
Why Leidos (LDOS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Buy, Hold or Sell Boeing Stock Before Q1 Earnings Release?
by Aparajita Dutta
Investors interested in BA stock should wait until April 23, taking into account its dismal performance at the bourses and elevated leverage.
Leidos (LDOS) Stock Moves -0.85%: What You Should Know
by Zacks Equity Research
In the latest trading session, Leidos (LDOS) closed at $138.24, marking a -0.85% move from the previous day.
Here is What to Know Beyond Why Leidos Holdings, Inc. (LDOS) is a Trending Stock
by Zacks Equity Research
Leidos (LDOS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Leidos (LDOS) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Leidos (LDOS) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the most recent trading session, Leidos (LDOS) closed at $141.40, indicating a -1.11% shift from the previous trading day.
Wall Street Bulls Look Optimistic About Leidos (LDOS): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Leidos (LDOS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
LDOS or HWM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LDOS vs. HWM: Which Stock Is the Better Value Option?
Why Leidos (LDOS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Leidos (LDOS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Boost Your Portfolio with Top Aerospace Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Leidos Reveals Its Latest Sea Dart Unmanned Undersea Vessel
by Zacks Equity Research
LDOS presents Sea Dart, an uncrewed underwater vessel that will help the U.S. Navy and commercial clients in a range of operations.
Leidos (LDOS) Stock Moves -0.18%: What You Should Know
by Zacks Equity Research
The latest trading day saw Leidos (LDOS) settling at $132.90, representing a -0.18% change from its previous close.
Are Investors Undervaluing Leidos (LDOS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is the Options Market Predicting a Spike in Leidos (LDOS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Leidos (LDOS) stock based on the movements in the options market lately.
Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos
by Zacks Equity Research
Context Therapeutics, Blue Bird, Dycom Industries and Leidos are part of the Zacks Screen of the Week article.
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains
by Sanghamitra Saha
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Context Therapeutics Inc. (CNTX), Blue Bird (BLBD), Dycom Industries (DY) and Leidos (LDOS).
LDOS vs. HWM: Which Stock Is the Better Value Option?
by Zacks Equity Research
LDOS vs. HWM: Which Stock Is the Better Value Option?
Lockheed Rides on Solid Order Growth and International Demand
by Zacks Equity Research
LMT continues to benefit from its steady inflow of orders and strong international demand for its broad range of products.
Here's Why You Should Add Embraer Stock to Your Portfolio Right Now
by Zacks Equity Research
ERJ makes a strong case for investment in the Aerospace sector, given its solid earnings growth prospects, return on equity, strong backlog and increasing investments.
Here's Why You Must Add Triumph Group Stock to Your Portfolio Now
by Zacks Equity Research
TGI is a solid pick in the aerospace-defense equipment industry, given its solid growth prospects, better solvency, strong liquidity and robust backlog.
Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride
by Zacks Equity Research
MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride have been highlighted in this Screen of The Week article.
5 High ROE Stocks to Buy as Markets Dip Despite Rate Cut Hopes
by Supriyo Bose
MPLX, LDOS, JAZZ, FTNT and PPC are some of the stocks with high ROE to profit from as markets falter on tariff concerns.
Is Leidos (LDOS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.